OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)‘s stock had its “market perform” rating reaffirmed by stock analysts at Leerink Swann in a research note issued on Monday. They currently have a $13.00 target price on the biopharmaceutical company’s stock. Leerink Swann’s target price indicates a potential upside of 14.64% from the company’s previous close. A number of other […]
